ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

Current Allergy & Clinical Immunology is a vital peer-reviewed journal published by the Allergy Society of South Africa, focused on advancing the field of immunology and allergy medicine. With an ISSN of 1609-3607, this journal offers crucial insights and research findings pertinent to the understanding and treatment of allergic conditions. Operating from South Africa, it features contributions from a diverse range of authors and professionals in the field. Published from 2008 to 2024, the journal plays an essential role in disseminating current knowledge, even as it holds a Q4 ranking in Immunology and Allergy and is positioned at the 4th percentile based on Scopus rankings. While not open access, it remains an important resource for researchers, practitioners, and students looking to stay informed on emerging trends and breakthroughs in allergy and clinical immunology.

Allergy Asthma & Respiratory Disease is a pioneering journal dedicated to advancing research and clinical practice in the fields of allergy, asthma, and related respiratory diseases. Published by the esteemed Korean Academy of Asthma Allergy & Clinical Immunology, this journal aims to disseminate high-quality, peer-reviewed articles that contribute to the understanding, diagnosis, and treatment of these prevalent health issues. Although it operates under a subscription model, it maintains a robust reputation for being a pivotal resource in respiratory health, attracting authors and researchers worldwide. The journal emphasizes interdisciplinary approaches and encourages submissions that span from molecular biology to public health perspectives, making it a vital platform for professionals, researchers, and students eager to deepen their knowledge in respiratory medicine. With a commitment to fostering academic discourse in South Korea and beyond, Allergy Asthma & Respiratory Disease is positioned as a significant contributor to the global conversation on respiratory health.

Frontiers in Allergy is a pioneering open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing the frontiers of research in the fields of Immunology and Infectious Diseases. Launched in 2020 and based in Lausanne, Switzerland, this journal provides a dynamic platform for researchers, professionals, and students to share innovative findings and insights related to allergic disorders and their broader immunological implications. With a respectable Q2 ranking in both Immunology and Allergy and Infectious Diseases categories, as well as being indexed in Scopus, this journal is emerging as a significant resource for the scientific community. The open-access model ensures wide dissemination of valuable knowledge, facilitating collaboration and breakthroughs in treatments and understanding of allergies and related conditions. Frontiers in Allergy invites contributions that drive forward the understanding of immune responses, allergy prevention, and management, solidifying its role as a crucial player in the sustainability and growth of health sciences.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

Immunity is a premier journal published by CELL PRESS that has positioned itself at the forefront of immunological research since its inception in 1994. With its ISSN 1074-7613 and E-ISSN 1097-4180, this prestigious journal is recognized for its significant contribution to the fields of Immunology, Allergy, and Infectious Diseases, consistently achieving a Q1 ranking in these categories as per 2023 metrics. The journal is highly esteemed within the academic community, holding impressive Scopus rankings—4th out of 344 in Infectious Diseases and 3rd in both Immunology and Immunology and Allergy—placing it in the 98th percentile. Although not an Open Access journal, it provides critical insights and research developments that empower researchers, healthcare professionals, and students alike. With a commitment to advancing scientific knowledge, Immunity is crucial for those interested in understanding immune responses and their implications for health and disease.

Allergy Asthma and Clinical Immunology, a pioneering open access journal published by BMC, has been at the forefront of immunological research since its inception in 2005. With an ISSN of 1710-1492, this UK-based journal has established a significant presence in the fields of Immunology, Allergy, and Pulmonary and Respiratory Medicine, achieving notable quartile rankings such as Q2 in Immunology and Allergy in 2023. It plays a crucial role in disseminating high-quality research that advances our understanding of allergy and asthma, making substantial contributions to clinical practices and public health. The journal embraces the principles of Open Access, allowing researchers, professionals, and students from around the globe to access its content freely, thus facilitating knowledge sharing and collaboration within the scientific community. As it converges towards 2024, Allergy Asthma and Clinical Immunology continues to attract impactful studies that drive innovation and improve patient care in the face of rapidly evolving challenges in immunological health.

Asia Pacific Allergy, published by Lippincott Williams & Wilkins, is a prominent academic journal dedicated to advancing research and clinical practice in the fields of dermatology, immunology, and allergy. With its ISSN 2233-8276 and E-ISSN 2233-8268, the journal provides a platform for innovative studies and reviews that cater to an international audience of researchers, healthcare professionals, and students involved in allergy and related disorders. Although it does not currently offer open access to its publications, the journal's robust output from 2015 to 2017 and its ongoing contribution to the literature from 2021 to 2024 showcase the evolving landscape of allergy research in the Asia Pacific region. Recognized in the 2023 Journal Citation Reports, it holds a Q2 ranking in Dermatology and a Q3 ranking in Immunology and Allergy, while its Scopus ranks further emphasize its significance within these domains, positioning it among the top journals in the field. As a source of cutting-edge research, Asia Pacific Allergy plays a vital role in fostering collaboration and knowledge dissemination, ultimately assisting in the betterment of patient care and treatment strategies across the region.

Gastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, focusing on the dynamic fields of immunology and allergy. With an ISSN of 0889-8561 and an E-ISSN of 1557-8607, this journal has consistently ranked in the Q2 category in both Immunology and Immunology and Allergy as per 2023 metrics, underscoring its critical role in academia. It provides cutting-edge research, comprehensive reviews, and practical insights that cater to the needs of researchers, clinicians, and students alike. Though the journal is not open access, it remains an essential resource for those involved in advancing knowledge and clinical practice in allergy and immunology. With its converged years stretching from 1987 to 2024, the journal serves as a rich repository of scientific advancements, fostering progress in diagnosis, treatment, and prevention of allergic diseases and immune disorders. Positioned within the United States and based in Philadelphia, it plays a vital role in promoting scholarly communication within these impactful fields.